Vardenafil 10mg - 4 Tablets

mitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitotanemitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. mitotane decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nefazodonenefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nefazodone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 10 mg is a selective phosphodiesterase type 5 inhibitor.
• It can improve the ability to achieve an erection.
• Maintain open communication with your healthcare provider.
• Use with caution in elderly patients.
• Report any unusual side effects promptly.
• The medication should not be used recreationally.
• Not recommended for use with certain antihypertensives.
• Effectiveness depends on correct timing and dosage.
• Avoid taking if you have severe liver disease.
• Always read the patient information leaflet.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavirnelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

How have regulatory and patent events influenced the market?

ketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lapatiniblapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lapatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors larotrectiniblarotrectinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors larotrectinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Dosage Modifications

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lenacapavirlenacapavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. lenacapavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/24 lithiumlithium and vardenafil both increase QTc interval. lithium and vardenafil both increase QTc interval. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetronnetupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nevirapinenevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Why is a prescription required for erectile dysfunction medicines?

lonafarniblonafarnib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling. lonafarnib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lopinavirlopinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lopinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Subscribe to MedicineNet's Men's Health Newsletter

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors lumefantrinelumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mavorixaformavorixafor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required. nifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinibnilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/72 hr olanzapineolanzapine and vardenafil both increase QTc interval. olanzapine and vardenafil both increase QTc interval. olodaterol inhaledvardenafil and olodaterol inhaled both increase QTc interval. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias vardenafil and olodaterol inhaled both increase QTc interval. osilodrostat and vardenafil both increase QTc interval. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

• Vardenafil 10 mg enhances natural erectile response.
• The medication is prescription-only in most countries.
• Common brand names include Levitra and Staxyn.
• Do not crush or split the tablet unless instructed.
• Using more than the prescribed dose can increase risk.
• Vardenafil is a phosphodiesterase inhibitor.
• It is not intended for use by women.
• Possible side effects include nasal congestion and dizziness.
• Seek medical advice if you experience priapism.
• Keep out of reach of children.

osimertinib and vardenafil both increase QTc interval.

• Vardenafil is generally safe when used as prescribed.
• The tablet is typically taken around 30 minutes before sex.
• Alcohol may enhance side effects like dizziness.
• Do not use vardenafil if you are taking nitrates.
• Keep a schedule of your medication use.
• Inform your doctor about other medications you are taking.
• Use only prescribed dosage to prevent adverse effects.
• Avoid certain foods that may interfere with absorption.
• Healthcare providers may adjust doses based on response.
• Proper storage extends the shelf life of the medication.

ozanimodozanimod and vardenafil both increase QTc interval. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. ozanimod and vardenafil both increase QTc interval.

vardenafil and pasireotide both increase QTc interval. pentobarbitalpentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What is the current market landscape for vardenafil hydrochloride?

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors istradefyllineistradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

How should I store vardenafil?

itraconazoleitraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivacaftorivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ivacaftor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ketoconazoleketoconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

4.1 Nitrates

mavorixafor will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for adverse effects of sensitive CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor). methylprednisolone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metronidazolemetronidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors metronidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What should I do if I miss a dose of vardenafil?

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Use alternatives if available.mifepristone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tadalista tablets mirtazapinemirtazapine and vardenafil both increase QTc interval. mirtazapine and vardenafil both increase QTc interval. mitapivatmitapivat decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic index when coadministered with mitapivat. phenytoinphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.